PDL BIOPHARMA, INC. 4/A
4/A · PDL BIOPHARMA, INC. · Filed Jan 28, 2016
Insider Transaction Report
Form 4/AAmended
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2014-04-10$8.22/sh+30,693$252,296→ 86,048 total
Footnotes (2)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,based upon the following schedule: 50% on December 12, 2015; 16.66% on December 12, 2016; 16.66% on December 12, 2017; and 16.66% on December 12, 2018.
- [F2]The amount of securities beneficially owned following the transaction above is being amended to remove 21,315 shares which were incorrectly reported as being beneficially owned by Mr. Stone.